Aug. 13 at 1:06 PM
$ALUR No update on FDA approval timeline. Let's assume it takes at least 12months (if there are no delays, further discussions, etc) to get full approval.
Cash balance on March 31, 2025 was
$20.4 million.
Q1 this year: CEO said "With our recent financings complete, we believe we have a cash runway through becoming EBITDA positive and receiving FDA approval of the Allurion Balloon."
As of June 30, 2025, the had cash and cash equivalents of
$12.7 million. in 1 quarter, ~8m was burnt. Sure we have these "restructuring". But revenue/profit is also declining. How is the company going to have enough cash runway till then?
A dilution is certainly coming before FDA approval. Very low volume stock and a bigger float and you might not even get much back from your shareholder value even when the "pop" happens with the FDA approval.
Not pleased.
